🇺🇸 Retapamulin (Altabax) in United States

9 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 9

Most-reported reactions

1. Complex Regional Pain Syndrome — 1 report (11.11%)
2. Condition Aggravated — 1 report (11.11%)
3. Dermatitis — 1 report (11.11%)
4. Excoriation — 1 report (11.11%)
5. Idiosyncratic Drug Reaction — 1 report (11.11%)
6. Neuropathy Peripheral — 1 report (11.11%)
7. Paraesthesia — 1 report (11.11%)
8. Paronychia — 1 report (11.11%)
9. Pruritus — 1 report (11.11%)

Source database →

Frequently asked questions

Is Retapamulin (Altabax) approved in United States?

Retapamulin (Altabax) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Retapamulin (Altabax) in United States?

The University of Texas Health Science Center, Houston is the originator. The local marketing authorisation holder may differ — check the official source linked above.